Simultaneous Video-EEG-ECG Monitoring to Identify Neurocardiac Dysfunction in Mouse Models of Epilepsy
January 29th, 2018
26.5K views
Here, we present a protocol to record brain and heart bio signals in mice using simultaneous video, electroencephalography (EEG), and electrocardiography (ECG). We also describe methods to analyze the resulting EEG-ECG recordings for seizures, EEG spectral power, cardiac function, and heart rate variability.
Overview
This protocol details the simultaneous recording of brain and heart biosignals in mice using video, electroencephalography (EEG), and electrocardiography (ECG). It aims to provide insights into epilepsy and neurocardiology by analyzing EEG-ECG recordings for seizures, cardiac function, and heart rate variability.
Key Study Components
Area of Science
- Neuroscience
- Cardiology
- Electrophysiology
Background
- This method allows for the investigation of the relationship between seizures and cardiac arrhythmias.
- It utilizes a tethered recording configuration for enhanced biopotential recording capabilities.
- The electrodes used are inexpensive and disposable, making the method accessible.
- Insights gained can contribute to understanding cardiac dysfunction in epilepsy.
Purpose of Study
- To measure brain and heart biosignals in mice.
- To explore the effects of gene mutations on spontaneous seizures.
- To investigate the impact of seizures on cardiac health.
Methods Used
- Simultaneous recording of video, EEG, and ECG.
- Analysis of EEG-ECG recordings for seizures and heart metrics.
- Use of a tethered recording setup for improved data collection.
- Application of relatively low-cost electrodes.
Main Results
- Identification of seizure events and their correlation with cardiac activity.
- Assessment of EEG spectral power and heart rate variability.
- Insights into the relationship between brain activity and cardiac function.
- Potential applications in neurocardiology research.
Conclusions
- This method provides a comprehensive approach to studying the interplay between brain and heart signals.
- It offers valuable insights into epilepsy and its effects on cardiac health.
- The protocol can be adapted for various research applications in neuroscience and cardiology.
Frequently Asked Questions
What is the main advantage of this recording method?
The tethered recording configuration allows for more biopotential recording channels compared to wireless systems.
How can this method contribute to epilepsy research?
It helps investigate the relationship between gene mutations, seizures, and cardiac arrhythmias.
What types of signals are recorded in this study?
Brain signals (EEG) and heart signals (ECG) are recorded simultaneously.
Are the electrodes used in this method expensive?
No, the electrodes are relatively inexpensive and disposable.
Can this method be used for other research areas?
Yes, it can be applied to neurocardiology to study associations between arrhythmias and brain activity.
What insights can be gained from the analysis of EEG-ECG recordings?
Insights into seizure activity, cardiac function, and heart rate variability can be obtained.
Executive Industry Relevance
Simultaneous video-EEG-ECG monitoring in mouse models enables mechanistic de-risking of neurocardiac pathways in epilepsy research by linking genetic mutations to seizure-induced cardiac arrhythmias. This approach supports target validation and phenotypic screening by providing quantitative, reproducible readouts of brain-heart interactions relevant to SUDEP risk assessment. The tethered configuration enhances signal fidelity and scalability for preclinical biomarker discovery and assay development pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses by correlating gene mutations (e.g., Kcna1) with spontaneous seizures and concurrent cardiac dysfunction.
- Operational Value: Enables functional target validation through simultaneous brain and heart biosignal acquisition in disease-relevant systems.
- Predictive Value: Supports mechanistic de-risking by identifying neurocardiac dysfunction as a biomarker of seizure severity and SUDEP susceptibility.
Screening & Assay Development
- Scientific Value: Prepares validated biological systems for downstream screening by establishing baseline EEG spectral power and heart rate variability metrics.
- Operational Value: Addresses assay standardization and reproducibility through tethered recording’s high channel count, bandwidth, and low-cost electrode infrastructure.
- Scalability: Facilitates platform reuse across epilepsy models and neurocardiology studies due to adaptability for EMG, plethysmography, or other biosignal integration.
Translational & Preclinical Research
- Translational Continuity: Connects discovery-phase neurocardiac dysfunction metrics to preclinical validation via quantifiable seizure duration, EEG spectral shifts, and R-R interval analysis.
- Risk-Adjusted Advancement: Informs go/no-go decisions by identifying arrhythmogenic substrates (e.g., AV conduction blocks) that correlate with epileptogenic burden.
- Predictive Confidence: Enhances translational biomarker alignment by demonstrating heart rate variability and conduction abnormalities as measurable outcomes of epileptic activity.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target hypothesis testing through lead identification by enabling objective quantification of neurocardiac phenotypes in genetic epilepsy models.
- Discovery Biology: Supports hypothesis testing and pathway clarification by linking Kcna1 deletion to seizure occurrence and cardiac arrhythmia induction.
- Screening: Delivers assay readiness through high-fidelity, multi-channel biopotential recording with detachable tethered connectors for longitudinal monitoring.
- Analytics: Provides quantitative readouts including seizure frequency, EEG spectral power shifts (delta increase, theta/alpha/beta/gamma decrease), and heart rate variability via detrended R-R interval series.
- Translational Research: Connects to preclinical continuity by validating ECG-derived biomarkers (e.g., P-wave without QRS complex) as indicators of seizure-related cardiac risk.
- Enterprise Reuse: Frames the tethered setup as a reusable electrophysiology platform adaptable to respiratory, muscular, or autonomic nervous system monitoring in disease models.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation through direct measurement of brain-heart crosstalk in epilepsy.
- Operational Value: Standardization and reproducibility via tethered architecture enabling consistent electrode placement and signal acquisition across studies.
- Strategic Value: Improved go/no-go decisions by reducing late-stage biological risk through early identification of cardiotoxic seizure phenotypes.
- Portfolio Impact: Risk-adjusted prioritization of compounds based on neurocardiac safety profiles in genetic seizure models.
Implementation Considerations
- Requires expertise in microsurgery, electrode implantation, and subcutaneous tunneling techniques for chronic biopotential recording.
- Dependent on stereotaxic frameworks, microdrills, and signal acquisition systems capable of high-bandwidth EEG and ECG sampling.
- Necessitates cross-team standardization of surgical protocols, anesthesia depth monitoring, and post-operative care to ensure data consistency.
- Involves adaptation considerations when extending the model to assess respiratory (plethysmography) or muscular (EMG) comorbidities in epilepsy.
- Practical limitations include tether-related movement restriction and infection risk from percutaneous connectors, mitigated by sterile technique and lightweight cabling.
Biopharma FAQs
Why does simultaneous EEG-ECG recording matter for target validation in epilepsy models?
It enables direct correlation of genetic mutations (e.g., Kcna1 deletion) with seizure onset and cardiac arrhythmias, providing mechanistic insight into neurocardiac dysfunction as a biomarker of target engagement and disease severity.
How does isolating independent variables (e.g., gene mutation) improve discovery pipeline reliability?
By using KCNA1 knockout mice, the method isolates the effect of a single gene on seizure generation and cardiac response, reducing confounding variables and increasing confidence in target-specific phenotypes.
What quantitative dependent variable measurements enable phenotypic screening in this model?
Seizure duration, EEG spectral power shifts (delta increase, theta/beta/gamma decrease), and heart rate variability from detrended R-R intervals provide quantifiable, high-resolution phenotypes for compound or genotype screening.
Why do replication requirements matter for cross-functional collaboration in neurocardiac studies?
Reproducible seizure and ECG metrics across animals ensure that findings on brain-heart interactions are robust, enabling reliable data sharing between discovery, toxicology, and translational teams.
What statistical analysis capabilities are required before implementing this method in preclinical workflows?
Proficiency in EEG spectral analysis, heart rate variability quantification, and event-locked averaging (e.g., pre-ictal, ictal, post-ictal) is needed to extract meaningful neurocardiac correlations from multi-modal biosignal data.
